Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:30 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Study to Evaluate Safety, Efficacy, Pharmacokinetics And Pharmacodynamics Of Avelumab In Combination With Either Crizotinib Or PF-06463922 In Patients With NSCLC. (Javelin Lung 101)
NCT02584634 · Pfizer · PHASE1/PHASE2 · terminated · last registry update 2023-07-07 · Non-small cell lung cancer · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “The study was terminated since there was no need for further safety or efficacy data to be collected. The participants having benefit from the Investigational treatments have been moved to a continuation study (NCT05059522)” | Open Targets' class: another study | Registry record, Pfizer |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CD274 in non-small cell lung cancer within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2024-02-28Phase 3 first posted: ETOP IBCSG Partners Foundation, Adjuvant durvalumab (NCT06284317)
- 2024-01-18Phase 3 first posted: Amgen, Tarlatamab + Durvalumab (NCT06211036)
- 2023-01-18Phase 3 first posted: AstraZeneca, Datopotamab deruxtecan + Durvalumab (NCT05687266)
- 2022-12-12Results posted on the registry: AstraZeneca, Durvalumab + Placebo for Olaparib (NCT03775486)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision